Oka Shinichi, Ikeda Kazuko, Takano Misao, Ogane Miwa, Tanuma Junko, Tsukada Kunihisa, Gatanaga Hiroyuki
AIDS Clinical Center, National Center for Global Health and Medicine, Tokyo, Japan.
Glob Health Med. 2020 Feb 29;2(1):9-17. doi: 10.35772/ghm.2019.01030.
Nearly 30% of Japanese hemophiliacs were infected with HIV-1 in the early 1980s. They have unique characteristics compared to HIV-1-infected individuals through other routes, including date of infection of 1986 or earlier, mean age of nearly 50 years, and common co-infection with hepatitis C, but rarely with other sexually transmitted diseases. Antiretroviral therapy (ART) was introduced in Japan in 1997. The clinical courses before and after 1997 were quite different. Careful analysis of the pre-1997 clinical data allowed expansion of our knowledge about the natural course and pathogenesis of the disease. Switching to the second receptor agents proved critical in subsequent disease progression. HIV-1 continued to escape immune pressure, pushing disease progression faster. In contrast, ART was effective enough to overcome the natural course. Prognosis improved dramatically and cause of death changed from AIDS-related opportunistic infections and malignancies before 1997, to hepatitis C virus-related cirrhosis and hepatocellular carcinoma (HCC) around 2010, and again to non-AIDS defining malignancies recently. In most cases, hepatitis C was cured with direct acting antiviral therapy. However, HCV progressed to cirrhosis in some cases and risk of HCC is still high among these patients. Together with improvement in anticoagulants and aging of the patients, risk of myocardial infarction has increased recently. In addition, the numbers of patients with life-style related co-morbidities, such as diabetes mellitus, hypertension, and chronic kidney disease have been also increasing. Finally, stigma is still an important barrier to a better life in HIV-1-positive individuals.
20世纪80年代初,近30%的日本血友病患者感染了HIV-1。与通过其他途径感染HIV-1的个体相比,他们具有独特的特征,包括感染时间在1986年或更早,平均年龄近50岁,丙型肝炎合并感染常见,但很少合并其他性传播疾病。1997年抗逆转录病毒疗法(ART)在日本开始应用。1997年前后的临床病程截然不同。对1997年前临床数据的仔细分析扩展了我们对该疾病自然病程和发病机制的认识。在后续疾病进展中,改用第二代受体药物被证明至关重要。HIV-1持续逃避免疫压力,使疾病进展加快。相比之下,ART足以有效克服自然病程。预后显著改善,死亡原因从1997年前的艾滋病相关机会性感染和恶性肿瘤,转变为2010年左右的丙型肝炎病毒相关肝硬化和肝细胞癌(HCC),最近又转变为非艾滋病定义的恶性肿瘤。在大多数情况下,直接抗病毒疗法治愈了丙型肝炎。然而,在某些情况下丙型肝炎进展为肝硬化,这些患者中HCC的风险仍然很高。随着抗凝剂的改进和患者年龄的增长,最近心肌梗死的风险增加。此外,患有糖尿病、高血压和慢性肾脏病等生活方式相关合并症的患者数量也在增加。最后,耻辱感仍然是HIV-1阳性个体过上更好生活的重要障碍。